⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
NNVC News
NanoViricides Inc.
DealFlow Discovery Conference Announces Initial Lineup of Presenting Companies Ahead of Next Week's Event
accessnewswire.com
COE
ACCS
ASNS
DRTS
AREB
BKYI
FUFU
CJMB
DVLT
FBLG
MEHA
HCTI
INDO
JUNS
KAPA
LIXT
MYSZ
NNVC
HOVR
NOMA
OPTT
OWLS
PERF
PHIO
PROP
PRPO
SJ
LITM
SOPA
SNGX
XHLD
TYGO
TIVC
TRX
WGRX
WWR
ZENA
FLGC
DealFlow Discovery Conference Announces Initial Lineup of Presenting Companies Ahead of Next Week's Event
accessnewswire.com
COE
ACCS
ASNS
DRTS
AREB
BKYI
FUFU
CJMB
DVLT
FBLG
MEHA
HCTI
INDO
JUNS
KAPA
LIXT
MYSZ
NNVC
HOVR
NOMA
OPTT
OWLS
PERF
PHIO
PROP
PRPO
SJ
LITM
SOPA
SNGX
XHLD
TYGO
TIVC
TRX
WGRX
WWR
ZENA
FLGC
NanoViricides to Present at the 3rd Annual DealFlow Discovery Conference
accessnewswire.com
NNVC
NanoViricides Comments on the Need for Broad-Spectrum Antivirals in Light of the Current Influenza Wave - NV-387 is Effective Against H3N2
accessnewswire.com
NNVC
NanoViricides Has Signed a Master Services Agreement with OnlyOrphansCote Regarding Orphan Drug Strategy of NV-387 for Treatment of MPox, Smallpox, and Measles
accessnewswire.com
NNVC
NanoViricides to Present at the Pharma Partnering Summit 2025 in Boston Today, November 14th - NV-387 is Effective Against H3N2
accessnewswire.com
NNVC
NanoViricides Announces Closing of $6 Million Registered Direct Offering and Concurrent Private Placement Priced at the Market Close
accessnewswire.com
NNVC
NanoViricides Announces Pricing of $6 Million Registered Direct Offering and Concurrent Private Placement Priced at the Market Close
accessnewswire.com
NNVC
NanoViricides Has Received Approval to Start Phase II Clinical Trial of NV-387 for the Treatment of MPox by the Regulatory Agency ACOREP of the Democratic Republic of Congo
accessnewswire.com
NNVC
NanoViricides Annual Shareholders Meeting to be Held at 10 am on Saturday, November 5th at on Saturday, November 8, 2025, at the Hampton Inn & Suites Stamford, CT
accessnewswire.com
NNVC